Cargando…

A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19

Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host’s immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for treatment and prevention of viral infection. Here, we u...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yadi, Liu, Yuan, Gupta, Shagun, Paramo, Mauricio I., Hou, Yuan, Mao, Chengsheng, Luo, Yuan, Judd, Julius, Wierbowski, Shayne, Bertolotti, Marta, Nerkar, Mriganka, Jehi, Lara, Drayman, Nir, Nicolaescu, Vlad, Gula, Haley, Tay, Savaş, Randall, Glenn, Lis, John T., Feschotte, Cédric, Erzurum, Serpil C., Cheng, Feixiong, Yu, Haiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176654/
https://www.ncbi.nlm.nih.gov/pubmed/35677070
http://dx.doi.org/10.21203/rs.3.rs-1354127/v2
_version_ 1784722711496359936
author Zhou, Yadi
Liu, Yuan
Gupta, Shagun
Paramo, Mauricio I.
Hou, Yuan
Mao, Chengsheng
Luo, Yuan
Judd, Julius
Wierbowski, Shayne
Bertolotti, Marta
Nerkar, Mriganka
Jehi, Lara
Drayman, Nir
Nicolaescu, Vlad
Gula, Haley
Tay, Savaş
Randall, Glenn
Lis, John T.
Feschotte, Cédric
Erzurum, Serpil C.
Cheng, Feixiong
Yu, Haiyuan
author_facet Zhou, Yadi
Liu, Yuan
Gupta, Shagun
Paramo, Mauricio I.
Hou, Yuan
Mao, Chengsheng
Luo, Yuan
Judd, Julius
Wierbowski, Shayne
Bertolotti, Marta
Nerkar, Mriganka
Jehi, Lara
Drayman, Nir
Nicolaescu, Vlad
Gula, Haley
Tay, Savaş
Randall, Glenn
Lis, John T.
Feschotte, Cédric
Erzurum, Serpil C.
Cheng, Feixiong
Yu, Haiyuan
author_sort Zhou, Yadi
collection PubMed
description Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host’s immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for treatment and prevention of viral infection. Here, we use high-throughput yeast two-hybrid and affinity purification followed by mass spectrometry to generate a comprehensive SARS-CoV-2-human protein-protein interactome network consisting of both binary and co-complex interactions. We report a total of 739 high-confidence interactions, showing the highest overlap of interaction partners among published datasets as well as the highest overlap with genes differentially expressed in samples (such as upper airway and bronchial epithelial cells) from patients with SARS-CoV-2 infection. Showcasing the utility of our network, we describe a novel interaction between the viral accessory protein ORF3a and the host zinc finger transcription factor ZNF579 to illustrate a SARS-CoV-2 factor mediating a direct impact on host transcription. Leveraging our interactome, we performed network-based drug screens for over 2,900 FDA-approved/investigational drugs and obtained a curated list of 23 drugs that had significant network proximities to SARS-CoV-2 host factors, one of which, carvedilol, showed promising antiviral properties. We performed electronic health record-based validation using two independent large-scale, longitudinal COVID-19 patient databases and found that carvedilol usage was associated with a significantly lowered probability (17%−20%, P < 0.001) of obtaining a SARS-CoV-2 positive test after adjusting various confounding factors. Carvedilol additionally showed anti-viral activity against SARS-CoV-2 in a human lung epithelial cell line [half maximal effective concentration (EC(50)) value of 4.1 μM], suggesting a mechanism for its beneficial effect in COVID-19. Our study demonstrates the value of large-scale network systems biology approaches for extracting biological insight from complex biological processes.
format Online
Article
Text
id pubmed-9176654
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-91766542022-06-09 A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19 Zhou, Yadi Liu, Yuan Gupta, Shagun Paramo, Mauricio I. Hou, Yuan Mao, Chengsheng Luo, Yuan Judd, Julius Wierbowski, Shayne Bertolotti, Marta Nerkar, Mriganka Jehi, Lara Drayman, Nir Nicolaescu, Vlad Gula, Haley Tay, Savaş Randall, Glenn Lis, John T. Feschotte, Cédric Erzurum, Serpil C. Cheng, Feixiong Yu, Haiyuan Res Sq Article Physical interactions between viral and host proteins are responsible for almost all aspects of the viral life cycle and the host’s immune response. Studying viral-host protein-protein interactions is thus crucial for identifying strategies for treatment and prevention of viral infection. Here, we use high-throughput yeast two-hybrid and affinity purification followed by mass spectrometry to generate a comprehensive SARS-CoV-2-human protein-protein interactome network consisting of both binary and co-complex interactions. We report a total of 739 high-confidence interactions, showing the highest overlap of interaction partners among published datasets as well as the highest overlap with genes differentially expressed in samples (such as upper airway and bronchial epithelial cells) from patients with SARS-CoV-2 infection. Showcasing the utility of our network, we describe a novel interaction between the viral accessory protein ORF3a and the host zinc finger transcription factor ZNF579 to illustrate a SARS-CoV-2 factor mediating a direct impact on host transcription. Leveraging our interactome, we performed network-based drug screens for over 2,900 FDA-approved/investigational drugs and obtained a curated list of 23 drugs that had significant network proximities to SARS-CoV-2 host factors, one of which, carvedilol, showed promising antiviral properties. We performed electronic health record-based validation using two independent large-scale, longitudinal COVID-19 patient databases and found that carvedilol usage was associated with a significantly lowered probability (17%−20%, P < 0.001) of obtaining a SARS-CoV-2 positive test after adjusting various confounding factors. Carvedilol additionally showed anti-viral activity against SARS-CoV-2 in a human lung epithelial cell line [half maximal effective concentration (EC(50)) value of 4.1 μM], suggesting a mechanism for its beneficial effect in COVID-19. Our study demonstrates the value of large-scale network systems biology approaches for extracting biological insight from complex biological processes. American Journal Experts 2022-06-07 /pmc/articles/PMC9176654/ /pubmed/35677070 http://dx.doi.org/10.21203/rs.3.rs-1354127/v2 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Article
Zhou, Yadi
Liu, Yuan
Gupta, Shagun
Paramo, Mauricio I.
Hou, Yuan
Mao, Chengsheng
Luo, Yuan
Judd, Julius
Wierbowski, Shayne
Bertolotti, Marta
Nerkar, Mriganka
Jehi, Lara
Drayman, Nir
Nicolaescu, Vlad
Gula, Haley
Tay, Savaş
Randall, Glenn
Lis, John T.
Feschotte, Cédric
Erzurum, Serpil C.
Cheng, Feixiong
Yu, Haiyuan
A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
title A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
title_full A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
title_fullStr A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
title_full_unstemmed A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
title_short A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19
title_sort comprehensive sars-cov-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176654/
https://www.ncbi.nlm.nih.gov/pubmed/35677070
http://dx.doi.org/10.21203/rs.3.rs-1354127/v2
work_keys_str_mv AT zhouyadi acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT liuyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT guptashagun acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT paramomauricioi acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT houyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT maochengsheng acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT luoyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT juddjulius acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT wierbowskishayne acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT bertolottimarta acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT nerkarmriganka acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT jehilara acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT draymannir acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT nicolaescuvlad acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT gulahaley acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT taysavas acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT randallglenn acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT lisjohnt acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT feschottecedric acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT erzurumserpilc acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT chengfeixiong acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT yuhaiyuan acomprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT zhouyadi comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT liuyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT guptashagun comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT paramomauricioi comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT houyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT maochengsheng comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT luoyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT juddjulius comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT wierbowskishayne comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT bertolottimarta comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT nerkarmriganka comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT jehilara comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT draymannir comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT nicolaescuvlad comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT gulahaley comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT taysavas comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT randallglenn comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT lisjohnt comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT feschottecedric comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT erzurumserpilc comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT chengfeixiong comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19
AT yuhaiyuan comprehensivesarscov2humanproteinproteininteractomenetworkidentifiespathobiologyandhosttargetingtherapiesforcovid19